Background: Darier’s disease (DD) is a rare autosomal dominant genodermatosis, characterized by abnormal keratinization and acantholysis. Although the clinical and genetic features of this inherited skin disorder have been well studied in the Caucasian population, very little is known about the clinical spectrum of the disorder in Asian populations. This retrospective study aimed to characterize the demographic and clinical features of multi-ethnic Malaysian patients with DD. Method : All new cases of DD seen in Department of Dermatology, Hospital Pulau Pinang over the 25-year period 1986-2010 were retrieved. Diagnosis was based on clinical features and was confirmed histopathologically in at least one of the family member. Details of the demographic and clinical data including treatment regimen were collected for analysis. Results: 15 affected patients from 6 unrelated families (60% female; mean age of onset 15.1; 60% Chinese, 40% Malays) were studied, of whom 14 (93.3%) were predominantly seborrhoeic involvement and only 1 (6.7%) had flexural predominant. Hand involvement was common (60%) which included 7 (46.7%) with nail changes, 6 (40.0%) with palmar pits and 4 (26.7%) patients had acrokeratosis verruciformis. Only 3 patients had oral mucosal involvement. No guttate leucoderma and hemorrhagic macules were noted in our cohort. Factors that exacerbate the disease in descending order of frequency were heat, sun exposure, infections and trauma. Neuropsychiatric abnormalities, including mental retardation, epilepsy and psychosis, have been observed in 4 (26.7%) patients. Nine (60%) patients were given systemic retinoid to control the disease. Conclusion: The clinical profiles of our patients were generally comparable to other Asian published data except rarity of co-occurrence of guttate leucoderma. Our findings add to the increasing bulk of Asian patient data valuable in the management of Darier’s disease.

Background: Tinea capitis (TC), a fungal infection of the scalp, hair follicles and hair shafts, is common among the paediatric population especially under tropical conditions1. The etiological factors vary between different regions of the world. Clinical presentation of tinea capitis varies widely from non-inflammatory to severe, painful inflammatory lesions. Aim: To look into the clinical manifestations, causative agents and the treatment pattern for tinea capitis in Penang Hospital. Methods: A retrospective study of all patients who were treated clinically for tinea capitis in Penang Hospital from January 2011 to June 2013. Results: There were a total of thirty nine patients treated for tinea capitis during this period. Tinea capitis was found to be most common in the 7-12 year age group (44%) with a male to female ratio of 2:1. Non-inflammatory type (54%) was more common then the inflammatory type. Twenty seven of them (69%) had positive fungal culture of their pluck hair roots. The most common dermatophyte detected was Microsporum canis (92%) followed by Trichophyton rubrum (4%) and Trichophyton metagraphyte (4%). Thirty-one (80%) of them were treated with griseofulvin at a dose of 10-15mg / kg /day. The rest were treated with itraconazole, terbinafine or fluconazole. All of them responded well to the treatment. In this cohort only one patient, has a second episode of infection a year later. He is a child who was concomitantly undergoing chemotherapy for acute lymphoblastic leukaemia. Conclusion: Tinea capitis is predominantly an infection of pre-adolescent children and M. canis was the most common dermatophyte isolated.

A fixed drug eruption (FDE) is a distinct drug induced reaction pattern that characteristically recurs at the same site on the skin or mucosa. We report a case of bullous FDE following ingestion of cetirizine, a common treatment for allergic disorders but a rare causative agent for cutaneous adverse drug reaction.

Background Rove beetle dermatitis is a peculiar form of acute irritant dermatitis following the contact with body fluid of an insect which is belonging to genus Paederus. This retrospective study is to evaluate the epidemiology and clinical manifestations of rove beetle dermatitis during the outbreak of rove beetle dermatitis in Penang (March 2009 - April 2009). Methods We describe 37 patients with clinical diagnosis of rove beetle dermatitis presented to our department. Only those patients with a definite history of contact with the insect were included in the study. Demographic characteristics, reason for referral and details of skin lesions were documented and analysed. Results Male patients outnumbered female patients - 21 males (56.8%); 16 females (43.2%). The mean age of patients was 28.3 years. Of the 37 patients, 18 patients (48.6%) were Malay, 14 Chinese (37.8%), 4 Indians (10.8%) and 1 foreigner (2.8%). The mean duration of lesions before presentation to our clinic was 3.4 days. The mean duration of lesions before presented to our clinic was 3.4 days. Symptom of burning sensation (25, 67.7%) was more pronounced than itching (6, 16.2%). Fourteen of our patients (37.8%) reported a positive family history. Clinically, the most common presentation consisted of linear, geographic, erythematous plaques with a ‘‘burnt’’ appearance. In 59.5% of patients, more than one lesion was present. Pustules and vesicles were seen in 12 (32.4%) and in 10 (27.1%) of the patients respectively. ‘‘Kissing lesions’’were seen in 5 (13.5%) patients. The neck and arms were the most common sites of involvement. Periorbital involvement occurred in 16.2% of patients. Only 8 patients (21.6%) were diagnosed to have “insect related dermatitis” at initial presentation. No one was referred as “rove beetle dermatitis”. Conclusion Rove beetle dermatitis is a common condition. Awareness of these condition and its clinical features will prevent misdiagnosis and unnecessary worry.

Introduction The efficacy of cyclosporine in the treatment of psoriasis is well established. However widespread use of it has been limited by concerns over adverse effects such as hypertension, renal impairment and the potential risk of malignancy. The aim of this study is to determine the profile of our local psoriasis patients treated with cyclosporine, their response to treatment, their tolerability and the side-effects experienced. Materials and Methods This is a retrospective study of all psoriasis patients treated with cyclosporine for more than one month from January 1996 to June 2007 at the Department of Dermatology Ipoh Hospital. Results There were a total 21 patients, 8 males and 13 females. Their mean age was 40 years. There were 7 Malays, 10 Chinese and 4 Indians. Cyclosporine was given as the second or third line of treatment. The average starting dose was 2.76mg/kg and maximum dose was 3.89mg/kg. Best response was noted after 3 months of treatment. Thirteen (61.9%) patients had excellent response, 4(19%) had good response, 3 (14.3%) had moderate response and 1(4.8%) had poor response. Thirteen (61.9%) patients developed raised serum creatinine level exceeding 30% of the baseline while on treatment but all of them improved when the dosages of cyclosporine were reduced. None of them developed renal failure. There were 5 patients who had hypertension while on cyclosporine therapy, 2 of them required antihypertensive agents while for the remaining 3, blood pressure normalized after dosage reduction. Other side effects reported include gastrointestinal upset, gum hypertrophy and hypertrichosis. Conclusion Cyclosporine is effective in the treatment of psoriasis but close monitoring of serum creatinine and blood pressure is needed.

Cutaneous B-cell pseudolymphoma (CBPL) is a reactive B-cell hyperplasia that clinically and histologically mimics cutaneous B-cell lymphoma (CBCL). Many different terms have been used to describe this condition such as lymphocytoma cutis and cutaneous lymphoid hyperplasia. This condition typically present as a solitary nodule or papule over face (cheek, nose and ear lobe), chest and upper extremities, but multiple lesions may also be present. A variety of stimuli are known to induce this condition but most cases have an unknown cause. We report 2 cases of CBPL, the causes of which could not be ascertained.

Objective The purpose of this study is to determine the outcome of patients with acne vulgaris treated with oral isotretinoin from January 2003 till January 2008. Methodology This is a 5-year retrospective study of patients with acne vulgaris who were started on oral isotretinoin from January 2003 to January 2008. Only patients who have completed at least 4 months of treatment were included. Case notes were retrieved and analyzed with regards to demographic data, total cumulative dose of oral isotretinoin, duration of treatment, average daily dose of isotretinoin, response, relapse and subsequent treatment. Patients who defaulted follow-up were contacted via phone to ascertain if they had any relapse. Laboratory data that were analyzed included serial liver enzymes, total cholesterol, triglyceride and LDL levels. Results A total of 110 case notes were reviewed but only 83 patients fulfilled the inclusion and exclusion criteria. Average daily dose of isotretinoin was 0.24 mg /kg/day and mean duration of treatment was 9.56 months. Mean total accumulated dose of isotretinoin was 61.96 ± 34.15 mg/kg (range from 11.18 mg/kg to 151.79mg/kg). There were only 6 (7.2%) patients who achieved total accumulated dose of more than 120mg/kg/day. All of our patients responded to treatment with 24 (28.9%) of them were in complete clearance. However, a high percentage (71.2%) of patients developed mucocutaneous side-effects out of which 27.7% required dose reduction. Relapse rate among those who completed treatment and follow up or contactable for at least 6 months post treatment was 24.2% (8 out of 33 patients). There were only 3 (3.6%) patients who developed raised transaminases during treatment but all were less than twice the upper normal limit. Mean total cholesterol, triglyceride and LDL level were significantly raised at 4 months of treatment when compared to the baseline (p<0.05). Conclusion Low dose Isotretinoin (<0.5mg/kg) is an effective treatment for moderate to severe acne vulgaris in our population. All of our patients showed good response to isotretinoin even though some of them relapsed subsequently. Intolerability as a result of mucocutaneous side-effects seems to be a challenging issue when starting isotretinoin in our population.

Background Autoimmune bullous diseases (ABD) represent a group of chronic blistering dermatoses in which management is often challenging. Epidemiologic data on these diseases in Malaysia has been limited. Objectives Our purpose was to study the spectrum of the various ABD presented to the Department of Dermatology, Ipoh Hospital, and to determine the clinico-epidemiological pattern of the 2 main ABD, namely pemphigus and bullous pemphigoid. Methodology We performed a retrospective review of records for all patients who were diagnosed with ABD confirmed by histopathology and direct immunofluorescence test in this centre between 2001 and 2005. The data were analyzed with regard to age, sex, ethnicity, subtypes of ABD, treatment provided and outcome. Results There were a total of 79 cases of ABD presented to us during this period. Bullous pemphigoid was observed to be the commonest (60.8%) followed by the pemphigus group (36.7%) with the mean incidence of 0.45/100,000/year and 0.28/100,000/year respectively.44% of patients were of ethnic Chinese origin. There was an overall female preponderance. The mean age of presentation was 65.5 years for bullous pemphigoid and 55 years for pemphigus group. The mean duration of disease before presentation was 1.6 months for bullous pemphigoid and 6.3 months for pemphigus. Various combinations of immunosuppressive agents were used to treat the patients. 48% of bullous pemphigoid cases were controlled with prednisolone alone while 67.9% of pemphigus group required at least 2 immunosuppressive agents to achieve disease control. Conclusion In our study population, bullous pemphigoid was more frequently seen than pemphigus.

Background Atopic eczema is a common dermatological condition seen in our practice in which the mainstay of treatment is topical medications. One of the main reasons for poor clinical response to therapy in atopic eczema is the lack of understanding of topical preparation usage and thus poor adherence to treatment. Objectives The aim of this study is to determine the effect of explanation and demonstration of topical medication on the clinical response of atopic eczema. Methodology Twenty newly diagnosed patients with atopic eczema who fulfilled the study criteria were recruited and randomized consecutively into 2 groups - A & B. All patients were assessed on the severity of the eczema using the six area, six sign atopic dermatitis severity score (SASSAD) and patients’ assessment of itch, sleep disturbance and irritability were recorded on 10-cm visual analogue scales. They were also assessed on their level of understanding on the proper usage of topical medications using a questionnaire. Group A then received explanation and demonstration on how to apply the topical medications while Group B was not educated on these. They were followed up 2 weeks after treatment and were re-evaluated on their understanding and the severity of their skin condition. This was followed by education by a dermatology nurse on the proper usage of topical medications for both groups. A third evaluation was done 2 weeks later. Results At baseline, 70% of the patients did not understand the potency of topical corticosteroid and between 20-30% of them did not know the correct sites, frequency, time and duration of each topical application prescribed. About two thirds of the patients claimed that they did not receive any explanation or demonstration from either their doctors or the pharmacy dispensers. After education on the proper usage of topical medications, the level of understanding improved to 100% for group A at visit 2 and group B at visit 3. A clinical improvement as measured by SASSAD score reduction was seen in both groups. In group A, a significant SASSAD score reduction of 49.5% (P=0.003) was seen after 2 weeks and it was sustainable, as evidenced by a further reduction to 67% (p=0.001) by week 4. In group B, a significant SASSAD score reduction (64.8%; p=0.002) was seen only at week 4 after patient education and demonstration. The magnitude of improvement in patients’ symptoms which included itch, sleep disturbance and irritability, measured by the patient using visual analog score, were only significant for group A after 4 weeks. Conclusions This study reinforces the importance of explanation and demonstration on the proper usage of topical medications in achieving better clinical response. Failure to explain on the use of topical medications may lead to patient dissatisfaction, poor compliance and lack of treatment efficacy.

Cutaneous vasculitis is a common manifestation of many systemic diseases. In the setting of asthma, eosinophilia and multiple disparate signs and symptoms, more serious cause of vasculitis like Churg-Strauss syndrome (CSS) should always be considered.